January 23, 2017 5:03 PM ET

Commercial Services and Supplies

Company Overview of Pharmaceutical Research and Manufacturers of America

Company Overview

Pharmaceutical Research and Manufacturers of America (PhRMA) represents the research-based pharmaceutical and biotechnology companies. The company advocates for public policies that encourage discovery of new medicines for patients by pharmaceutical and biotechnology research companies. Its members consist of 3M Pharmaceuticals, Berlex Laboratories, Inc., GE Healthcare, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Millennium Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Wyeth, and Pfizer Inc. PhRMA was founded in 1958 and is based in Washington, DC.

950 F Street, NW

Suite 300

Washington, DC 20004

United States

Founded in 1958





Key Executives for Pharmaceutical Research and Manufacturers of America

Chief Executive Officer and President
Age: 65
President of International Section
Chief Medical Officer
Senior Vice President of External Affairs
Senior Vice President of Communications
Compensation as of Fiscal Year 2016.

Pharmaceutical Research and Manufacturers of America Key Developments

Pharmaceutical Research and Manufacturers of America Announces Board Changes

The Pharmaceutical Research and Manufacturers of America (PhRMA) announced Joaquin Duato, worldwide chairman, pharmaceuticals, Johnson & Johnson, has been named chairman of PhRMA's board of directors. Duato formerly held the position of chairman-elect of the PhRMA board and succeeds George Scangos, who has stepped down as CEO of Biogen. Duato has served as worldwide chairman, pharmaceuticals at Johnson & Johnson since January 2011. During his 28-year career at Johnson & Johnson, Duato has worked across the company's pharmaceuticals and medical device business segments, held regional chairman roles and led local market businesses in a variety of countries and regions. As a dual citizen of Spain and the United States, he brings a unique international perspective to his work.

Pharmaceutical Research and Manufacturers of America Announces Management Changes

The Pharmaceutical Research and Manufacturers of America announced that Robert Zirkelbach has been named executive vice president of public affairs. Zirkelbach assumes the responsibilities of Josephine Martin, who announced her intent to pursue new opportunities.

Pharmaceutical Research and Manufacturers of America Highlights Continued Progress and Ongoing Efforts in the Research and Development of New Treatments

Pharmaceutical Research and Manufacturers of America (PhRMA) has highlighted continued progress and ongoing efforts in the research and development of new treatments for the more than 30 million Americans with diabetes and diabetes-related conditions. According to the report, there are now more than 170 medicines in development for type 1 diabetes, type 2 diabetes and related diseases, such as chronic kidney disease. The report highlights critical advancements in treatment that enable better adherence to medications and ultimately improved quality of health for patients. Diabetes is the seventh leading cause of death in the United States; in addition, 86 million Americans are considered pre-diabetic, which places them at higher risk to develop type 2 diabetes. The cost of diagnosed diabetes is $245 billion in the United States, and biopharmaceutical researchers are tirelessly working to find new lifesaving and life-changing treatments and cures to address this complex disease and the costs associated with it. For diabetes patients the continuous monitoring of blood sugar levels and numerous types of medications make the disease challenging to manage. The advancement of treatments and development of new medications supports better adherence by patients, which is crucial to avoiding hospitalizations. One study estimates improved adherence could avoid nearly 350,000 hospitalizations and nearly 700,000 emergency room visits each year in the United States, which results in reduced medical spending as great as $5,000 per patient annually. The report also acknowledges a positive trend in new diagnoses of diabetes, with the U.S. Centers for Disease Control and Prevention (CDC) citing a decrease in the rate of new diabetes cases diagnosed annually.

Similar Private Companies By Industry

Company Name Region
$1 Energy Fund, Inc. United States
1 Class Corp United States
1 Solution Corp United States
1-800 Junk-USA United States
100 Pablo, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Pharmaceutical Research and Manufacturers of America, please visit www.phrma.org. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.